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In this issue of Circulation, Meier et al 2 describe for the first time the causal involvement of innate immune cells in the pathogenesis of mitral valve disease. The authors conducted their studies in K/B.g7 T-cell receptor transgenic mice (TCR mice) that express a T-cell receptor that recognizes the self-peptide glucose-6-phosphate isomerase. The resulting autoantibody production causes erosive polyarthritis and mitral valve inflammation. Mitral valves become fibrotic and accumulate myeloid cells that express the fractalkine receptor CX3CR1. Genetic deletion of CX3CR1 protects mice from valve fibrosis and inflammation, likely because this receptor regulates myeloid cell migration and survival. 3 Using multicolor flow cytometry, the authors identify a CD301b/MGL2 mononuclear cell population as a key protagonist of mitral valve disease in TCR mice. They characterize this population as CXC3CR1
+ mononuclear phagocytes and ascribe to them the characteristics of macrophages and dendritic cells. The authors report that ablation of CD301b + cells in TCR mice reduces valve inflammation and fibrosis significantly, suggesting a causal pathogenic role for cells expressing this receptor in autoantibody-triggered pathologies of the mitral valve. Using intracellular flow cytometry, the authors found that CD301b + myeloid cells produce the inflammatory cytokines interleukin-6 and tumor necrosis factor-α. These preclinical data are accompanied by identification of CD301 + macrophages in human rheumatic valves that were obtained during valve replacement surgery. Mechanistically, using several genetic mouse models, the authors report that cell type-specific ablation of the small tyrosine kinase Syk in mononuclear phagocytes using CX3CR1-cre prevents mitral valve fibrosis and inflammation, including reduced infiltration of CD301b + myeloid cells, which express less interleukin-6 and tumor necrosis factor-α after Syk deletion. Interleukin-1β is an important inflam-matory stimulus of atherosclerosis and a cytokine expressed in leukocytes infiltrating stenotic aortic valves. 4 In the model used by Meier et al, targeting interleukin-1β did not prevent recruitment of disease-promoting myeloid cells into mitral valves, arguing for alternative inflammatory pathways.
The presence of macrophages in healthy and diseased myocardium of mice and humans has been recognized in recent years, but the cells' role in tissue homeostasis and cardiovascular disease is not yet fully understood. This is especially true for heart valves. In their present article, Meier et al convincingly show the importance of myeloid cells for the initiation and progression of autoimmune heart valve pathology, which was previously thought to be driven mainly by the adaptive immune system. Although the detection of cardiac leukocytes with standard immunohistochemistry techniques was often hampered by limited sensitivity, improvements in imaging technology now enable the analysis of leukocyte subsets and phenotypes in much more detail. With the use of optical tissueclearing procedures before whole-mount imaging of mitral valves in combination with myeloid cell-specific expression of fluorescent proteins, the current article Macrophages also participate in other valvular pathologies. For example, macrophages were detected in clinical samples of aortic stenosis, where inflammation initiates degenerative valve changes leading to calcification. 5 Although it currently remains unclear if myeloid cells are present in healthy human heart valves, this is likely the case, because leukocytes have been visualized with confocal imaging in aortic and atrioventricular valves in healthy mice. 6 These cells were described as dendritic cells based on CD11c promoter-driven fluorescent protein expression. 6 There is an ongoing debate on how to best phenotypically distinguish macrophages and dendritic cells in the cardiovascular system 7 ; hence, the exact cellular characteristics of leukocytes in heart valves remain somewhat unresolved. The gating strategy used by Meier et al did not aim to distinguish macrophages from dendritic cells. CD301b, whose expression was used to drive cell ablation in the TCR mouse, is expressed by both macrophages and dendritic cells. 8 The authors conclude that local myeloid cell proliferation dominates valve pathology in rheumatic heart disease, but also show that cell recruitment is critical, which relies on the cell adhesion molecule vascular cell adhesion molecule 1 expressed on valvular endothelial cells. As long as there are no known organ-specific promotors for macrophages, it is not possible to distinguish the regional impact of the conditional gene knockouts used by Meier on the valves itself from distant, systemic sites of action. The same is true for systemic treatment with neutralizing antibodies. Remote hematopoietic organs are important coordinators of leukocyte supply to sites of inflammation in cardiovascular pathologies. 9 Hence, it cannot be excluded that the observed effects after antibody treatment against vascular cell adhesion molecule 1 or myeloid cell-specific deletion of its ligand very late antigen-4 are attributable to processes in lymphatic organs, bone marrow, or spleen. This also holds true for myeloid cell-specific ablation of Syk, which is highly expressed by all hematopoietic lineage cells. 10 Because hematopoietic organs are likely activated in autoimmune disease, the aspect of localization warrants further studies. Of note, the continued joint inflammation after ablation of CD301b + cells in TCR mice does support the notion that local valve processes play an important role.
This study highlights the importance of inflammation and specifically myeloid cells in the development of heart valve pathologies triggered by autoimmune disorders. Next, it will be interesting to explore whether the findings translate to the broader collective of patients with degenerative valve disease. Meier et al reported that the aortic valve is also affected in TCR mice, albeit less frequently than the mitral valve. The presence of macrophages in clinical samples of calcific aortic valve stenosis has been demonstrated with conventional immunohistochemistry; indeed, chronic inflammation is considered a major feature in calcific aortic valve disease, preceding valve calcification. 11 Thus, the pathobiology of calcific aortic stenosis may share parallels to mechanisms observed in mitral valve disease by Meier et al, especially with respect to endothelial damage executed by mechanical stress, resulting in the upregulation of adhesion molecules and the recruitment of circulating leukocytes. 12 Mitral regurgitation is a frequent complication after myocardial infarction leading to heart failure and associated mortality. Myocardial infarction strongly induces the expression of tumor necrosis factor-α and interleukin-6, 13 and Meier et al show that both molecules are necessary for the recruitment of myeloid cells in heart valve disease. Albeit the altered post-myocardial infarction ventricular geometry decisively contributes to mechanical stress on the valve and its insufficiency, leukocyte infiltration may also contribute to pathology in this setting. Mitral valve endothelial cells express higher levels of vascular cell adhesion molecule 1 after myocardial infarction, which recruits leukocytes. 14, 15 Moreover, higher amounts of inflammatory cells have been detected in clinical specimens of myxomatous mitral valve disease. 16 In summary, the work by Meier et al is a trail blazer, because it clearly and elegantly demonstrates the causal involvement of innate immune cells during the development of mitral valve disease. The presence of similar cells in murine and human valve pathology provides a strong translational perspective. We will have to add the heart valves to the list of tissues that leukocytes frequent, and yet another cardiovascular disease to the list of conditions to which myeloid cells contribute. With the era of immunotherapy dawning, we next have to explore how and when to intervene without compromising host defense, especially critical questions when dealing with chronic disease. The positive experience in noncardiovascular conditions such as rheumatoid arthritis and the success of immunotherapy in cancer illuminate that this is possible.
